EU’s von der Leyen confronts fresh no confidence challenges

EU’s von der Leyen confronts fresh no confidence challenges


European Commission President Ursula von der Leyen and NATO Secretary General Mark Rutte hold a joint press statement in Brussels, Belgium on September 30, 2025.

Anadolu | Anadolu | Getty Images

European Commission President Ursula von der Leyen will face bids to remove her for the second time in three months when hard-right and left groups in the European Parliament present no-confidence motions this week.

Although the motions of censure have almost no chance of reaching the two-thirds majority of votes required to unseat von der Leyen, they could expose more general disquiet over her leadership and destabilise the EU assembly, whose backing is required to pass legislation.

The motions are set to be proposed on Monday by France’s far right and hard left – Jordan Bardella, president of the National Rally, and Manon Aubry of France Unbowed – followed by von der Leyen’s defence, and spots for leaders of all party groups.

The votes take place on Thursday. For von der Leyen this is not a new experience. She also faced a no-confidence motion in July from mainly far-right lawmakers, which she comfortably survived.

However, parties outside the mainstream have realised that triggering previously seldom-used censure motions is easy to achieve after the 2024 elections swelled the far right to more than 100 lawmakers, with only 72 required to back one.

In the case of the left, it has also co-opted one lawmaker from the centre-left Socialist and Democrats group and several Greens.

The two censure motions differ, the right’s complaining about “misguided” green policies and a failure to address illegal migration, while the left’s highlights the EU’s inaction over Gaza.

However, both sides agree that von der Leyen accepted an unbalanced tariff deal with the United States and that the Commission’s proposed EU-Mercosur trade deal is a threat to farmers and the environment.

Both will be put to votes in the parliament in the coming months, with the outcomes unclear.



Source

Sun Pharma shares jump 5% as India’s largest drugmaker to buy U.S. firm Organon in .75 billion deal
World

Sun Pharma shares jump 5% as India’s largest drugmaker to buy U.S. firm Organon in $11.75 billion deal

SHANGHAI, CHINA – NOVEMBER 05: People visit the booth of Organon during the 7th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 5, 2024 in Shanghai, China. The 7th China International Import Expo (CIIE) kicked off in Shanghai on November 5. (Photo by Tang Yanjun/China News Service/VCG via […]

Read More
China industrial profits jump 15.8% in March, fueled by AI and chip boom despite oil shock risks
World

China industrial profits jump 15.8% in March, fueled by AI and chip boom despite oil shock risks

Employees work on the production line of solar panels at a workshop of Jiangsu DMEGC New Energy Co., Ltd. on July 22, 2025 in Suqian, Jiangsu Province of China. Vcg | Visual China Group | Getty Images Profits at China’s industrial firms grew at their fastest pace in six months in March, even as the […]

Read More
CNBC Daily Open: Security scare and stalled Iran talks
World

CNBC Daily Open: Security scare and stalled Iran talks

President Donald Trump on stage as gun shots heard at the White House Correspondents Dinner in Washington, D.C. on April 25th, 2026. Hello, this is Hui Jie writing to you from Singapore. Welcome to another edition of CNBC’s Daily Open. The attempted shooting at the White House Correspondents’ Association Dinner dominated headlines over the weekend, […]

Read More